Long‐Term Outcomes in Belatacept‐ Versus Cyclosporine‐Treated Recipients of Extended Criteria Donor Kidneys: Final Results From BENEFIT‐EXT, a Phase III Randomized Study

In the Belatacept Evaluation of Nephroprotection and Efficacy as First‐Line Immunosuppression Trial–Extended Criteria Donors (BENEFIT‐EXT), extended criteria donor kidney recipients were randomized to receive belatacept‐based (more intense [MI] or less intense [LI]) or cyclosporine‐based immunosuppr...

Descripción completa

Detalles Bibliográficos
Autores principales: Durrbach, A., Pestana, J. M., Florman, S., del Carmen Rial, M., Rostaing, L., Kuypers, D., Matas, A., Wekerle, T., Polinsky, M., Meier‐Kriesche, H. U., Munier, S., Grinyó, J. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5516151/
https://www.ncbi.nlm.nih.gov/pubmed/27130868
http://dx.doi.org/10.1111/ajt.13830

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5516151/
https://www.ncbi.nlm.nih.gov/pubmed/27130868
http://dx.doi.org/10.1111/ajt.13830

Ejemplares similares